Alderly unions balk at AstraZeneca's R&D layoffs

AZ CEO Pascal Soriot

First, AstraZeneca ($AZN) announced plans for a major R&D reorganization aimed at putting its scientists closer to the action inside a major global biotech hub. Now comes the union backlash, complete with rumblings of a possible strike aimed at forcing the new CEO to backpedal on the move. Report